<DOC>
	<DOCNO>NCT00280098</DOCNO>
	<brief_summary>Evaluation safety efficacy docetaxel treatment advance hormone refractory prostate cancer condition daily practise .</brief_summary>
	<brief_title>Docetaxel Treatment Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>The following information clinical trial provide information purpose allow patient physician initial discussion trial . This information intend complete information trial , contain consideration may relevant potential participation trial , replace advice personal physician health professional . Main criterion list hereafter : Patients advanced prostate cancer , without previous chemotherapy , progress hormonal treatment , performance status 1 2 Other cytostatic treatment , malignity , severe comorbidity</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>